Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ionis Pharmaceuticals, Inc.
This is a multi-center, randomized, double-blind, placebo-controlled study in 617 participants. Participants will be randomized to receive olezarsen or placebo in a 53-week treatment period. The length of participation in the study will be approximately 78 weeks, which includes an up to 12-week screening period, a 53-week treatment period, and a 13-week post-treatment evaluation period or transition to open-label extension (OLE) study with up to 1-year treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification
Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study.
You may not be if
Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening
Alanine aminotransferase or aspartate aminotransferase \> 3.0 × upper limit of normal
Total bilirubin \> upper limit of normal unless due to Gilbert's syndrome